tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

AZN Stock Latest News

AstraZeneca completes agreement with KYM Biosciences for CMG901
The FlyAstraZeneca completes agreement with KYM Biosciences for CMG901
1d ago
AZN
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
The FlyOppenheimer emerging biotech analyst to hold analyst/industry conference call
4d ago
AZN
AMAM
Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints
The FlyIonis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints
4d ago
AZN
IONS
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
The FlyOppenheimer emerging biotech analyst to hold analyst/industry conference call
4d ago
AZN
AMAM
AstraZeneca says Calquence conditionally approved in China for first indication
The FlyAstraZeneca says Calquence conditionally approved in China for first indication
8d ago
AZN
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
The FlyOppenheimer emerging biotech analyst to hold analyst/industry conference call
9d ago
AZN
AMAM
JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call
The FlyJPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call
15d ago
AZN
BCAB
AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
The FlyAstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
16d ago
AZN
AstraZeneca announces ADAURA trial meets secondary endpoint
The FlyAstraZeneca announces ADAURA trial meets secondary endpoint
22d ago
AZN
AstraZeneca announces AEGEAN trial demonstrated statistical significance
The FlyAstraZeneca announces AEGEAN trial demonstrated statistical significance
22d ago
AZN
AstraZeneca says Tagrisso showed ‘strong’ overall survival benefit in trial
The FlyAstraZeneca says Tagrisso showed ‘strong’ overall survival benefit in trial
22d ago
AZN
AstraZeneca says Imfinzi significantly improved event-free survival in AEGEAN
The FlyAstraZeneca says Imfinzi significantly improved event-free survival in AEGEAN
22d ago
AZN
Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
The FlyGuggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
24d ago
AZN
CINC
Mineralys Therapeutics initiated with an Outperform at Evercore ISI
The FlyMineralys Therapeutics initiated with an Outperform at Evercore ISI
24d ago
AZN
MLYS
AstraZeneca, Daiichi Sankyo announce Enhertu met the prespecified target for ORR
The FlyAstraZeneca, Daiichi Sankyo announce Enhertu met the prespecified target for ORR
25d ago
AZN
AstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02
The FlyAstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02
25d ago
AZN
AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC
The FlyAstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC
29d ago
AZN
MRK
Prenetics announces formation of scientific advisory board
The FlyPrenetics announces formation of scientific advisory board
29d ago
AZN
PRE
AstraZeneca completes acquisition of CinCor Pharma
The FlyAstraZeneca completes acquisition of CinCor Pharma
1M ago
AZN
CINC
AstraZeneca reports Enhertu approved in China for metastatic breast cancer
The FlyAstraZeneca reports Enhertu approved in China for metastatic breast cancer
1M ago
AZN
AstraZeneca announces license agreement with KYM Biosciences for CMG901
The FlyAstraZeneca announces license agreement with KYM Biosciences for CMG901
1M ago
AZN
AstraZeneca reports Imfinzi plus Imjudo approved in EU for NSCLC
The FlyAstraZeneca reports Imfinzi plus Imjudo approved in EU for NSCLC
1M ago
AZN
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterEtf Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.